Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-820 in major depressive disorder
NCT06235905Phase 2Completed
- Sponsor
- Navitor Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mefluleucine in major depressive disorder (MDD), sponsored by Navitor Pharmaceuticals. Primary endpoint: Hamilton Depression Rating Scale-6 Items at 10 days. Started Feb 2024; status: completed.
02
Drugs
mefluleucine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06235905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235905.